The transcription factor PU.1 (Purine-rich DNA binding, SPI1) is a key regulator of hematopoiesis, whose level is influenced by transcription through its enhancers and its post-transcriptional degradation via microRNA-155 (miR-155). The degree of transcriptional regulation of the PU.1 gene is influenced by repression via DNA methylation, as well as other epigenetic factors, such as those related to progenitor maturation status, which is modulated by the transcription factor Myeloblastosis oncogene (MYB). In this work, we show that combinatorial treatment of acute myeloid leukemia (AML) cells with DNA methylation inhibitors (5-Azacytidine), MYB inhibitors (Celastrol), and anti-miR-155 (AM155) ideally leads to overproduction of PU.1. We also show that PU.1 reactivation can be compensated by miR-155 and that only a combined approach leads to sustained PU.1 derepression, even at the protein level. The triple effect on increasing PU.1 levels in myeloblasts stimulates the myeloid transcriptional program while inhibiting cell survival and proliferation, leading to partial leukemic differentiation.

BIOCEV 1st Medical Faculty Charles University 25250 Vestec Czech Republic

See more in PubMed

Nowak D., Stewart D., Koeffler H.P. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113:3655–3665. doi: 10.1182/blood-2009-01-198911. PubMed DOI PMC

Dahl R., Walsh J.C., Lancki D., Laslo P., Iyer S.R., Singh H., Simon M.C. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat. Immunol. 2003;4:1029–1036. doi: 10.1038/ni973. PubMed DOI

Rosenbauer F., Wagner K., Kutok J.L., Iwasaki H., Le Beau M.M., Okuno Y., Akashi K., Fiering S., Tenen D.G. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat. Genet. 2004;36:624–630. doi: 10.1038/ng1361. PubMed DOI

Metcalf D., Dakic A., Mifsud S., Di Rago L., Wu L., Nutt S. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc. Natl. Acad. Sci. USA. 2006;103:1486–1491. doi: 10.1073/pnas.0510616103. PubMed DOI PMC

Will B., Vogler T.O., Narayanagari S., Bartholdy B., Todorova T.I., da Silva Ferreira M., Chen J., Yu Y., Mayer J., Barreyro L., et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nat. Med. 2015;21:1172–1181. doi: 10.1038/nm.3936. PubMed DOI PMC

Kastner P., Chan S. PU.1: A crucial and versatile player in hematopoiesis and leukemia. Int. J. Biochem. Cell Biol. 2008;40:22–27. doi: 10.1016/j.biocel.2007.01.026. PubMed DOI

Zhu X., Zhang H., Qian M., Zhao X., Yang W., Wang P., Zhang J., Wang K. The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J. Hematol. Oncol. 2012;5:22. doi: 10.1186/1756-8722-5-22. PubMed DOI PMC

Leddin M., Perrod C., Hoogenkamp M., Ghani S., Assi S., Heinz S., Wilson N.K., Follows G., Schonheit J., Vockentanz L., et al. Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood. 2011;117:2827–2838. doi: 10.1182/blood-2010-08-302976. PubMed DOI PMC

Ebralidze A.K., Guibal F.C., Steidl U., Zhang P., Lee S., Bartholdy B., Jorda M.A., Petkova V., Rosenbauer F., Huang G., et al. PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev. 2008;22:2085–2092. doi: 10.1101/gad.1654808. PubMed DOI PMC

Ghani S., Riemke P., Schonheit J., Lenze D., Stumm J., Hoogenkamp M., Lagendijk A., Heinz S., Bonifer C., Bakkers J., et al. Macrophage development from HSCs requires PU.1-coordinated microRNA expression. Blood. 2011;118:2275–2284. doi: 10.1182/blood-2011-02-335141. PubMed DOI PMC

O’Connell R.M., Rao D.S., Chaudhuri A.A., Boldin M.P., Taganov K.D., Nicoll J., Paquette R.L., Baltimore D. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 2008;205:585–594. doi: 10.1084/jem.20072108. PubMed DOI PMC

Waldron T., De Dominici M., Soliera A.R., Audia A., Iacobucci I., Lonetti A., Martinelli G., Zhang Y., Martinez R., Hyslop T., et al. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia. 2012;26:644–653. doi: 10.1038/leu.2011.264. PubMed DOI PMC

Basova P., Pospisil V., Savvulidi F., Burda P., Vargova K., Stanek L., Dluhosova M., Kuzmova E., Jonasova A., Steidl U., et al. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 2014;33:4735–4745. doi: 10.1038/onc.2013.414. PubMed DOI

Vargova K., Curik N., Burda P., Basova P., Kulvait V., Pospisil V., Savvulidi F., Kokavec J., Necas E., Berkova A., et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117:3816–3825. doi: 10.1182/blood-2010-05-285064. PubMed DOI

Curik N., Burda P., Vargova K., Pospisil V., Belickova M., Vlckova P., Savvulidi F., Necas E., Hajkova H., Haskovec C., et al. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia. 2012;26:1804–1811. doi: 10.1038/leu.2012.47. PubMed DOI

van Riel B., Rosenbauer F. Epigenetic control of hematopoiesis: The PU.1 chromatin connection. Biol. Chem. 2014;395:1265–1274. doi: 10.1515/hsz-2014-0195. PubMed DOI

Uttarkar S., Dasse E., Coulibaly A., Steinmann S., Jakobs A., Schomburg C., Trentmann A., Jose J., Schlenke P., Berdel W.E., et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood. 2016;127:1173–1182. doi: 10.1182/blood-2015-09-668632. PubMed DOI

Bejar R., Lord A., Stevenson K., Bar-Natan M., Perez-Ladaga A., Zaneveld J., Wang H., Caughey B., Stojanov P., Getz G., et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–2712. doi: 10.1182/blood-2014-06-582809. PubMed DOI PMC

Yu X., Ruan X., Zhang J., Zhao Q. Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia. Molecules. 2016;21:574. doi: 10.3390/molecules21050574. PubMed DOI PMC

Coulibaly A., Haas A., Steinmann S., Jakobs A., Schmidt T.J., Klempnauer K.H. The natural anti-tumor compound Celastrol targets a Myb-C/EBPbeta-p300 transcriptional module implicated in myeloid gene expression. PLoS ONE. 2018;13:e0190934. doi: 10.1371/journal.pone.0190934. PubMed DOI PMC

Wallace J.A., Kagele D.A., Eiring A.M., Kim C.N., Hu R., Runtsch M.C., Alexander M., Huffaker T.B., Lee S.H., Patel A.B., et al. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood. 2017;129:3074–3086. doi: 10.1182/blood-2016-09-740209. PubMed DOI PMC

Durual S., Rideau A., Ruault-Jungblut S., Cossali D., Beris P., Piguet V., Matthes T. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia. 2007;21:1050–1059. doi: 10.1038/sj.leu.2404645. PubMed DOI

Rao G., Rekhtman N., Cheng G., Krasikov T., Skoultchi A.I. Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene. 1997;14:123–131. doi: 10.1038/sj.onc.1200807. PubMed DOI

Ramaswamy K., Forbes L., Minuesa G., Gindin T., Brown F., Kharas M.G., Krivtsov A.V., Armstrong S.A., Still E., de Stanchina E., et al. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat. Commun. 2018;9:110. doi: 10.1038/s41467-017-02618-6. PubMed DOI PMC

Yusenko M., Jakobs A., Klempnauer K.H. A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity. Sci. Rep. 2018;8:13159. doi: 10.1038/s41598-018-31620-1. PubMed DOI PMC

Yusenko M.V., Trentmann A., Andersson M.K., Ghani L.A., Jakobs A., Arteaga Paz M.F., Mikesch J.H., Peter von Kries J., Stenman G., Klempnauer K.H. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Lett. 2020;479:61–70. doi: 10.1016/j.canlet.2020.01.039. PubMed DOI

Yin L., Cai W., Liang Y., Yao J., Wang X., Shen J. In situ self-assembly of Au-antimiR-155 nanocomplexes mediates TLR3-dependent apoptosis in hepatocellular carcinoma cells. Aging. 2020;13:241–261. doi: 10.18632/aging.103799. PubMed DOI PMC

D’Abundo L., Callegari E., Bresin A., Chillemi A., Elamin B.K., Guerriero P., Huang X., Saccenti E., Hussein E., Casciano F., et al. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene. 2017;36:6617–6626. doi: 10.1038/onc.2017.269. PubMed DOI

Malik S., Bahal R. Investigation of PLGA nanoparticles in conjunction with nuclear localization sequence for enhanced delivery of antimiR phosphorothioates in cancer cells in vitro. J. Nanobiotechnology. 2019;17:57. doi: 10.1186/s12951-019-0490-2. PubMed DOI PMC

Medyouf H., Mossner M., Jann J.C., Nolte F., Raffel S., Herrmann C., Lier A., Eisen C., Nowak V., Zens B., et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014;14:824–837. doi: 10.1016/j.stem.2014.02.014. PubMed DOI

Ebinger S., Ozdemir E.Z., Ziegenhain C., Tiedt S., Castro Alves C., Grunert M., Dworzak M., Lutz C., Turati V.A., Enver T., et al. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell. 2016;30:849–862. doi: 10.1016/j.ccell.2016.11.002. PubMed DOI PMC